Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00417833
Phase
PHASE2/PHASE3
Status
Terminated

Conditions

  • Choroidal Neovascularization
  • Diabetic Proliferative Retinopathy
  • Vascular Vein Oclussion

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Key Dates

First listed
Jan 4, 2007
Start date
Dec 31, 2005
Status verified
May 2024
Completion
Jul 31, 2006

Study Design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP

Related Studies